EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 240 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR 10 Tips for National Cancer Prevention Month February 10, 2021 Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer. November 21, 2019 FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell... December 3, 2024 Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk... January 13, 2021 Load more HOT NEWS First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer... Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... Science Surgery: ‘How are children’s cancers different from adult’s cancers?’ Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From...
